Skip to main content

Rucsanda Pinteac

Institutions of which they are part

Postdoctoral researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Rucsanda Pinteac

Institutions of which they are part

Postdoctoral researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Projects

Búsqueda de compuestos que bloquean la acción de la chitinase 3-like 1 sobre las neuronas como tratamiento para los pacientes con esclerosis múltiple

IP: Manuel Comabella Lopez
Collaborators: Berta Miró Cau, Andreu Vilaseca Jolonch, Elisa Marín Ordovás, Rucsanda Pinteac, Rucsanda Pinteac
Funding agency: Instituto de Salud Carlos III
Funding: 233750
Reference: PI24/01088
Duration: 01/01/2025 - 31/12/2027

Modelos humanizados basados en células madre pluripotentes inducidas para estudiar la patología oligodendroglial y estrategias de remielinización en pacientes con esclerosis múltiple

IP: Andres Miguez Gonzalez
Collaborators: Gloria López Comellas, Elisa Marín Ordovás, Rucsanda Pinteac, Rucsanda Pinteac
Funding agency: Instituto de Salud Carlos III
Funding: 140000
Reference: PI24/01117
Duration: 01/01/2025 - 31/12/2027

Human induced pluripotent stem cell-based chimeric mice to study astrocyte pathology and neuroprotective strategies in multiple sclerosis patients

IP: Manuel Comabella Lopez
Collaborators: Andres Miguez Gonzalez, Rucsanda Pinteac, Rucsanda Pinteac
Funding agency: Instituto de Salud Carlos III
Funding: 286770
Reference: PI21/01611
Duration: 01/01/2022 - 30/06/2025

Liquid biopsy in multiple sclerosis: A non-invasive approach for disease prognosis and drug discovery...

IP: Liquid biopsy in multiple sclerosis: A non-invasive approach for disease prognosis and drug discovery...
Collaborators: Jordi Rio Izquierdo, Ana Zabalza de Torres, Rucsanda Pinteac, Rucsanda Pinteac
Funding agency: Instituto de Salud Carlos III
Funding: 140360
Reference: PI20/01697
Duration: 01/01/2021 - 30/06/2025

Related news

The Spider-MS tool estimates the probability that a patient will experience various long-term clinical events and will help personalize the follow-up and treatment of each person living with the disease.

The results show that live attenuated vaccines against measles, rubella, mumps and varicella do not increase the risk of relapses in people with multiple sclerosis.

Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research

Related professionals

Inmaculada Jimenez Ariza

Inmaculada Jimenez Ariza

Gestió i Administració
Accounting and Revenue Unit
Finance Directorate
Read more
Rosa Lloria Verges

Rosa Lloria Verges

Administration and Management
Pneumology
Read more
Josep Maria de Bergua Domingo

Josep Maria de Bergua Domingo

Predoctoral researcher
Bioengineering, Cell Therapy and Surgery in Congenital Malformations
Read more
Elena Huerga Núñez

Elena Huerga Núñez

Administration and Management
Neuroradiology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.